![](/images/graphics-bg.png)
Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
المؤلفون المشاركون
Drazilova, Sylvia
Janicko, Martin
Jarcuska, Peter
Gazda, Jakub
المصدر
Canadian Journal of Gastroenterology and Hepatology
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-11، 11ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-08-13
دولة النشر
مصر
عدد الصفحات
11
التخصصات الرئيسية
الملخص EN
Patients with chronic hepatitis C have both higher prevalence of diabetes mellitus type 2 (T2DM) and increased cardiovascular risk compared to never infected people.
Sustained viral response (SVR) achievement led to decreasing incidence and prevalence of T2DM during the interferon era of HCV treatment.
Currently, direct-acting antiviral drugs (DAA) are the gold standard for treating HCV infection, while yielding SVR in nearly all patients.
In chronic HCV patients with T2DM (prediabetes most likely too), DAA therapy is associated with both better fasting glucose and glycated hemoglobin (HbA1C) controls; thus reducing pharmacotherapy in a certain part of patients is possible.
Papers mentioned in the review confirmed DAA role in both total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) increase.
This alteration was accompanied by an increase in high-density lipoprotein cholesterol (HDL-C) and a decrease in triglycerides (TG) verified by most of the studies.
However, the clinical significance of lipoprotein alterations caused by DAA therapy has not been explained yet.
Moreover, DAA treatment of chronic hepatitis C improves hypertension control and atherosclerotic plaques.
It is very likely that DAA therapeutic regimens will decrease both T2DM prevalence and cardiovascular risk in chronic hepatitis C patients; further research, however, is needed.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Drazilova, Sylvia& Gazda, Jakub& Janicko, Martin& Jarcuska, Peter. 2018. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Canadian Journal of Gastroenterology and Hepatology،Vol. 2018, no. 2018, pp.1-11.
https://search.emarefa.net/detail/BIM-1130988
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Drazilova, Sylvia…[et al.]. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Canadian Journal of Gastroenterology and Hepatology No. 2018 (2018), pp.1-11.
https://search.emarefa.net/detail/BIM-1130988
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Drazilova, Sylvia& Gazda, Jakub& Janicko, Martin& Jarcuska, Peter. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Canadian Journal of Gastroenterology and Hepatology. 2018. Vol. 2018, no. 2018, pp.1-11.
https://search.emarefa.net/detail/BIM-1130988
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1130988
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)